Clinical Trial Update: Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism. [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating low molecular weight heparin followed by dabigatran for acute intermediate-risk pulmonary embolism was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism

Drugs mentioned

• Dabigatran (Dabigatran etexilate)
• Low molecular weight heparin (low molecular weight heparin)

Snippet

Sponsor: Prof. Stavros Konstantinides, MD | Conditions: Pulmonary Embolism | Phase 4 | Status: TERMINATED